Gregory MacMichael - Coya Therapeutics, Chief Officer
| COYA Stock | 6.38 0.12 1.85% |
Executive
Gregory MacMichael is Chief Officer of Coya Therapeutics, Common
| Age | 68 |
| Address | 5850 San Felipe Street, Houston, TX, United States, 77057 |
| Phone | 800 587 8170 |
| Web | https://www.coyatherapeutics.com |
Coya Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2934) % which means that it has lost $0.2934 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5083) %, meaning that it created substantial loss on money invested by shareholders. Coya Therapeutics,'s management efficiency ratios could be used to measure how well Coya Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.2. In addition to that, Return On Capital Employed is expected to decline to -0.23. At present, Coya Therapeutics,'s Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 43.3 M, whereas Net Tangible Assets are projected to grow to (14.7 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sheng Cui | NewAmsterdam Pharma | N/A | |
| Jason Amello | Tscan Therapeutics | 56 | |
| Dr MS | Fennec Pharmaceuticals | N/A | |
| Nicole Leber | Lantern Pharma | N/A | |
| Sarika Gulhar | Opthea | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| MBA Jones | NewAmsterdam Pharma | 60 | |
| Barbara Leyman | Sutro Biopharma | N/A | |
| John Doyle | Cognition Therapeutics | 47 | |
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Bobby Horn | Cognition Therapeutics | N/A | |
| Mayur Somaiya | NewAmsterdam Pharma | 50 | |
| Trevor Hallam | Sutro Biopharma | 65 | |
| Jim Jacobson | NewAmsterdam Pharma | N/A | |
| KerriAnn Millar | Cue Biopharma | 54 | |
| Sean Proehl | Dermata Therapeutics | N/A | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| David Socks | Hillevax | 49 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Maria MBA | Dermata Therapeutics | 73 | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 |
Coya Therapeutics, Common Leadership Team
Elected by the shareholders, the Coya Therapeutics,'s board of directors comprises two types of representatives: Coya Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coya. The board's role is to monitor Coya Therapeutics,'s management team and ensure that shareholders' interests are well served. Coya Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coya Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arun Swaminathan, Chief Officer | ||
| Howard Berman, Executive Chair | ||
| David Snyder, CFO COO | ||
| Gregory MacMichael, Chief Officer | ||
| FAPA DO, President Officer | ||
| Aaron Thome, Head Platform | ||
| Michelle Frazier, Senior Affairs | ||
| Karen MS, Senior Operations |
Coya Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coya Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.17) % | ||||
| Current Valuation | 122.42 M | ||||
| Shares Outstanding | 16.71 M | ||||
| Shares Owned By Insiders | 7.03 % | ||||
| Shares Owned By Institutions | 19.96 % | ||||
| Number Of Shares Shorted | 196.52 K | ||||
| Price To Book | 3.33 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Coya Therapeutics, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Coya Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Coya Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Coya Therapeutics, Common Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coya Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coya Therapeutics,. If investors know Coya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coya Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.687 | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Coya Therapeutics, Common is measured differently than its book value, which is the value of Coya that is recorded on the company's balance sheet. Investors also form their own opinion of Coya Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Coya Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coya Therapeutics,'s market value can be influenced by many factors that don't directly affect Coya Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coya Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Coya Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coya Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.